Blood Pressure Tablets Recalled

Amerisource Health Services is recalling 695 cartons of verapamil hydrochloride extended-release tablets. According to the April 26, 2023, US Food and Drug Administration (FDA) Enforcement Report, product testing revealed dissolution results above specified values.

The recall affects verapamil hydrochloride extended-release tablets, 180 mg, 100-tablet cartons (carton NDC 60687-504-01, unit dose NDC 60687-504-11), from lots 1008622 and 1010026 (Exp 2/29/24). The affected tablets were distributed by American Health Packaging, Columbus, Ohio, throughout the United States.

Amerisource Health Services voluntarily initiated the recall March 16, 2023. On April 14, 2023, the FDA designated the recall Class II, signaling use of the product could cause temporary or medically reversible adverse health consequences. A remote possibility of serious harm also exists.

Verapamil hydrochloride extended-release tablets are available with a prescription for the treatment of hypertension.